Author: admin

Meet MyConnectz, the Powerhouse Marketing Agency Founded by Business and Technology Specialist Crystal Franklin

Franklin melds together her deep expertise in business and tech to offer bespoke marketing strategies that leverage evidence-based practices for SEO, online visibility, sales, and more

MyConnectz has officially debuted, bringing a powerhouse marketing solution to the table that melds together founder Crystal Franklin’s deep passion and expertise in business and technology.  

MyConnectz focuses on digital transformation, taking brands from the ground floor of creation all the way to internet domination. Statistics show that 87% of B2B marketers are using content marketing to successfully generate leads and that 97% of marketers achieved their goals with marketing in 2023. Franklin’s love for tech and business fueled her passion for marketing, especially in the digital sector. This was the spark for MyConnectz.

At MyConnectz, evidence-based strategies are used to carve out digital transformation for each client. Some of these strategies include website design, customer portal design, branding services, mobile marketing, press release distribution, and bio linking. Turning to MyConnectz press release distribution, Franklin positions her clients with exposure on top networks including ABC, CBS, and NBC while achieving Google News visibility.

“In the digital age, content is king but engagement is the kingdom,” said Franklin. “It’s not just about what you say, but how you make them feel.” 

With this philosophy in hand, Franklin works one-on-one with clients to ensure that their target demographics are being met with the right messages at the right time. This is accomplished while simultaneously balancing expertly crafted branding at every step to ensure the perfect digital presence that leads to traffic and leads.

From logo design to full website design and custom mobile branding and marketing solutions, the team at MyConnectz is a full-service, scalable digital marketing partner for entrepreneurs and businesses at every step of the way.

“I was impressed with the press release services from MyConnectz. They managed to get our product launch covered by major networks like NBC and CBS, creating a significant buzz around our brand,” said one of the first clients to book with MyConnectz.

Learn more and book now by visiting https://www.myconnectz.com/.

ABOUT MYCONNECTZ

MyConnectz is a premier marketing agency offering innovative digital design, branding, and mobile marketing strategies. Follow MyConnectz at :

Instagram: @myconnectztech

Facebook: @myconnectz

YouTube: @myconnectz9405

Media Contact
Company Name: MyConnectz
Contact Person: Crystal Franklin
Email: Send Email
Phone: 210-640-1829
Country: United States
Website: https://www.myconnectz.com/

Introducing CoolSculpting Elite at Cryo Body Perfections: A Breakthrough in Body Sculpting and Fat Reduction

Introducing CoolSculpting Elite at Cryo Body Perfections: A Breakthrough in Body Sculpting and Fat Reduction

“We are passionate about creating lasting body transformations to help people feel more confident, sexy and vibrant,” said Margret De Bruyn, Director
Cryo Body Perfections has revolutionized non-invasive fat reduction with the introduction of CoolSculpting Elite, marking a breakthrough in body sculpting technology. Offering dramatic transformations this updated approach motivates individuals to achieve the best versions of themselves. As the premier authority in body sculpting, Cryo Body Perfections invites you on a wonderful journey—a time to change and embrace a future where you can be the best you can be.

McAllen, TX – Cryo Body Perfections, a leading authority in non-invasive body sculpting, proudly introduces the latest advancement in fat reduction technology: CoolSculpting Elite. With an unparalleled track record of over 5000 successful treatments in 8 years, Cryo Body Perfections stands at the forefront of transforming lives through innovative, FDA-cleared solutions.

This updated and improved service, along with its new pricing model, ensures that clients experience the most effective, dramatic results possible. CoolSculpting Elite represents a significant leap forward in cryolipolysis technology, offering a more efficient and comfortable experience.

“Envision a future where you feel fantastic and brimming with confidence, thanks to the most advanced CoolSculpting system available. Imagine the peace of mind knowing that 30% of our clientele are individuals seeking to correct unsatisfactory results from other providers,” said Margret De Bruyn, Director.

Cryo Body Perfections is passionate about offering a unique solution that maximizes results, ensuring that every client leaves feeling better than ever. “Our dedication to excellence and innovation has positioned Cryo Body Perfections as the go-to destination for those seeking to reshape their lives without surgery,” said Emma Castillo, Marketing Coordinator at Cryo Body Perfections. “The introduction of CoolSculpting Elite, coupled with our expertise in correcting previous treatments, underscores our commitment to providing only the most effective, breakthrough technologies to our clients,” she added.

CoolSculpting’s legacy of success, supported by years of hard science from Harvard University doctors, has resulted in 15 million happy customers worldwide. Celebrities and everyday individuals alike have turned to CoolSculpting for a safe, non-invasive way to reduce unwanted fat.

Now, with CoolSculpting Elite, Cryo Body Perfections is set to redefine what it means to achieve body perfection. Interested parties should not miss out on the opportunity to undergo a transformative, confidence-boosting experience with Cryo Body Perfections.

“Say goodbye to the old you. Get the body you want with a treatment plan tailored to your body and goals. Our updated services and pricing model make it the perfect time to take the first step towards the dramatic changes you’ve been dreaming of,” added Margret De Bruyn.

About Cryo Body Perfections:

For eight years, Cryo Body Perfections has been the premier destination for non-invasive body sculpting and fat reduction treatments. Their dedication to providing groundbreaking, safe, and effective treatments has made them the authority in the field, correcting previous unsatisfactory procedures and delivering over 5000 successful treatments. With CoolSculpting Elite, Cryo Body Perfections continues its mission to offer the most innovative solutions to their clients, ensuring unparalleled satisfaction and results.

To discover more about Cryo Body Perfections and CoolSculpting Elite, interested parties may schedule a FREE consultation at www.cryobp.com or contact the company directly at 956-627-1231.

Facebook/Meta: https://www.facebook.com/cryobp

Instagram: https://www.instagram.com/cryobp

Media Contact
Company Name: Cryo Body Perfections
Contact Person: Margret De Bruyn, Director
Email: Send Email
Phone: 956-627-1231
Address:1101 Vine Ave, Ste H
City: McAllen
State: Texas 78504
Country: United States
Website: https://www.cryobp.com

European Basketball Trainer Gea Uguccioni Elevates Players’ Skills with innovative methods

“Success is not absence of failure, it’s persistence through failure”
Gea Uguccioni, one of the very few female I’m Possible skills trainers, is devoted to discovering and overcoming flaws in the skill set of aspiring basketball stars through innovative methods. The Italian native’s mission is helping basketball players to perfect their skills and techniques, allowing them to achieve peak performance and reducing the gap between them and their dreams.

Gea Uguccioni, a 26-year-old Italian native residing in East Moline, Illinois, is the only European female certified as I’m Possible Skills trainer and one of the few to have achieved this prestigious certification worldwide. This distinction places her among an elite group of trainers dedicated to enhancing players’ skills through ingenious, visionary methods.

With her unparalleled expertise, Uguccioni is committed to improving and developing players’ careers through innovative techniques, demonstrating her ability to excel in the competitive world of basketball training and allowing young players to reach their ambitious goals.

“My objective is to discover weaknesses in the skill set of players and find solutions to overcome those flaws. I work on skill enhancement details, such as footwork, ball handling, body position, finishing.”

Including over 700 skill details and founded by the famous NBA skills coach Mikah Lancaster, the I’m Possible system is the most detailed method in the basketball universe and allows trainers to refine players’ techniques and achieve peak performance.

In a recent interview, Uguccioni shared her inspiring journey from playing basketball in her hometown of Pesaro, Italy, to becoming a sought-after skills trainer. Her passion for basketball ignited at the age of 11, leading her to pursue her dream of playing college basketball in the US and eventually transitioning into a trainer career.

“I’ve always believed in the power of skill enhancement to elevate players’ performance on the court,” said Uguccioni, who firmly believes the most important quality a basketball player should possess to be successful on the court is versatility. Her dedication to detail and relentless pursuit of excellence set her apart as a trailblazer in the field of basketball training.

“As a certified I’m Possible Skills trainer, my goal is to make a meaningful impact on players’ lives by honing their skills and preparing them for success in their careers,” Uguccioni explained.

“I’m committed to providing players with the tools they need to excel in a highly competitive environment.”

Uguccioni’s proficiency as a basketball trainer makes a huge difference in a player’s career development and longevity. “While players work on the game enhancement part – such as pick and roll, defense – with their teams, they work on the athletic enhancement part – lifting weights and cardio – with their team’s athletic trainers, the skills enhancement aspect is often neglected,” the Italian trainer explains. “Nevertheless, that’s the part that makes players most complete and takes their game to the next level.”

Her athlete’s mentality and her belief that success is not absence of failure but it’s the persistence through failure are other aspects that allow her to help many young players reach their dreams.

Gea Uguccioni’s success story serves as a testament to the value of hard work, dedication, and expertise.

Media Contact
Company Name: SNW
Contact Person: John Dixon
Email: Send Email
Country: United States
Website: www.zacalaw.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: European Basketball Trainer Gea Uguccioni Elevates Players\’ Skills with innovative methods

Zero Abuse Project awarded $1.2 million for top-rated child abuse prevention in Minnesota

St. Paul, MN – April 19, 2024 – Zero Abuse Project, a national nonprofit organization, announced that the March 23 federal budget signed into law by US Government included an appropriation of $1.2 million for the nonprofit to provide a child abuse prevention program in Minnesota. The congressionally-directed spending was jointly sponsored by Sen. Amy Klobuchar (D-MN) and Sen. Tina Smith (D-MN).

The child abuse prevention program will be developed and operated by Zero Abuse Project’s Jacob Wetterling Resource Center, whose abuse prevention education curriculum, Empower Me!, has been rated by the Minnesota Children’s Alliance to be among the top five curriculums in the nation. Empower Me!, which is currently used in schools in Minnesota, Arkansas, and Maryland, is aimed at children from first to third grades. The new federal funding will be used to develop, evaluate, and deliver age-appropriate prevention curricula to older students, as well as increase public awareness of strategies for preventing child abuse.

It is estimated that one in four girls and one in six boys will experience abuse before the age of 18. In 2021, Minnesota had more than 5,000 confirmed victims of child maltreatment, and 26% of them were victims of abuse. Studies show that the overwhelming majority of victims will not disclose their abuse for many years.

Zero Abuse Project CEO and abuse survivor Jeffrey Dion believes this funding is an important step towards eliminating child abuse.

“This is a crime that happens in the shadows,” says Dion. “The best way to combat it is by breaking the stigma and increasing transparency. It is the responsibility of adults to keep kids safe, but we can make kids smart—but not scared—by providing kids, parents, teachers, and others the tools they need to create a world where every child is free from abuse.”

“As a former prosecutor, I know that child abuse is a life and death issue,” says Sen. Klobuchar. “This federal funding will be used to combat child abuse in Minnesota by providing parents, teachers, law enforcement, and others the resources they need to identify and respond to signs of abuse. With this investment, we’re taking a step forward toward keeping our children safe.”

“Investing in child abuse prevention is critical for safeguarding the physical and emotional health of children, fostering healthy communities, and building a future where every child can grow up in an environment free from fear, trauma, and the lasting impacts of abuse,” says Sen. Smith. “Projects like this are exactly the type of thing the federal government should be a partner in. I was glad to advocate for the work Zero Abuse Project is doing and help secure this federal funding to support them in protecting children.”

In addition to the prevention education programs offered by the Jacob Wetterling Resource Center, Zero Abuse Project offers training and technical assistance for county attorneys and law enforcement on the effective and trauma-informed investigation and prosecution of child abuse. Its Child Advocacy Studies (CAST) program provides experiential education for students pursuing careers in child protection at more than 90 colleges and universities. Its interactive SurvivorSpace website offers information, resources, and support for adult survivors of child abuse.

For more information on trainings, events, and joining the fight against child abuse, please visit www.zeroabuseproject.org, or follow us on social media via Facebook/LinkedIn/X: @ZeroAbuseProj

Headquartered in St. Paul, Minnesota, Zero Abuse Project is a 501(c)(3) committed to transforming institutions in order to effectively prevent, recognize, and respond to child abuse.

Media Contact
Company Name: ZERO ABUSE PROJECT
Contact Person: Mike Valente – Director of Communications
Email: Send Email
Phone: 571.312.9803 x 719
Address:366 Jackson Street, Suite 300
City: St. Paul
State: Minnesota
Country: United States
Website: www.zeroabuseproject.org

Focal Segmental Glomerulosclerosis Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | B. Braun Melsungen, Beckman Coulter, Bayer

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Focal Segmental Glomerulosclerosis pipeline constitutes 15+ key companies continuously working towards developing 18+ Focal Segmental Glomerulosclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Focal Segmental Glomerulosclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Focal Segmental Glomerulosclerosis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Focal Segmental Glomerulosclerosis Market.

 

Some of the key takeaways from the Focal Segmental Glomerulosclerosis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Focal Segmental Glomerulosclerosis treatment therapies with a considerable amount of success over the years. 
  • Focal Segmental Glomerulosclerosis companies working in the treatment market are Ceptur Therapeutics, Evergreen Therapeutics, Delta4, Certa Therapeutics, Boehringer Ingelheim, River 3 Renal Corp, Dimerix Bioscience, Travere Therapeutics, Inc., and others, are developing therapies for the Focal Segmental Glomerulosclerosis treatment 
  • Emerging Focal Segmental Glomerulosclerosis therapies in the different phases of clinical trials are- Research programme Oligonucleotides, EG-102, D4-101-02, OCX-063, BI764198, R3R 01, DMX-200, Sparsentan, and others are expected to have a significant impact on the Focal Segmental Glomerulosclerosis market in the coming years.   
  • In August 2022, The company finished its scheduled Type A meeting with the FDA regarding a potential submission seeking accelerated approval for sparsentan to treat FSGS. The FDA suggested that the study’s design in the DUPLEX Study retained the possibility for complete approval, contingent on the study’s completion, and advised the company to pursue standard approval based on the two-year eGFR slope.
  • In February 2022, Goldfinch Bio revealed encouraging initial findings from a phase 2 clinical study assessing gfb-887 as a personalized medicine for individuals diagnosed with focal segmental glomerulosclerosis (FSGS).

 

Focal Segmental Glomerulosclerosis Overview

The hallmark of focal and segmental obliteration of glomerular capillary tufts inside enlarged matrix is known as focal segmental glomerular sclerosis (FSGS). FSGS is categorized based on the location and nature of the sclerotic lesion into collapsing, tip, cellular, perihilar, and not otherwise defined forms.

 

Get a Free Sample PDF Report to know more about Focal Segmental Glomerulosclerosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight

 

Emerging Focal Segmental Glomerulosclerosis Drugs Under Different Phases of Clinical Development Include:

  • Research programme Oligonucleotides: Ceptur Therapeutics
  • EG-102: Evergreen Therapeutics
  • D4-101-02: Delta4
  • OCX-063: Certa Therapeutics
  • BI764198: Boehringer Ingelheim
  • R3R 01: River 3 Renal Corp
  • DMX-200: Dimerix Bioscience
  • Sparsentan: Travere Therapeutics, Inc.

 

Focal Segmental Glomerulosclerosis Route of Administration

Focal Segmental Glomerulosclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Intravenous
  • Subcutaneous
  • Intramuscular

 

Focal Segmental Glomerulosclerosis Molecule Type

Focal Segmental Glomerulosclerosis Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide

 

Focal Segmental Glomerulosclerosis Pipeline Therapeutics Assessment

  • Focal Segmental Glomerulosclerosis Assessment by Product Type
  • Focal Segmental Glomerulosclerosis By Stage and Product Type
  • Focal Segmental Glomerulosclerosis Assessment by Route of Administration
  • Focal Segmental Glomerulosclerosis By Stage and Route of Administration
  • Focal Segmental Glomerulosclerosis Assessment by Molecule Type
  • Focal Segmental Glomerulosclerosis by Stage and Molecule Type

 

DelveInsight’s Focal Segmental Glomerulosclerosis Report covers around 18+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Focal Segmental Glomerulosclerosis product details are provided in the report. Download the Focal Segmental Glomerulosclerosis pipeline report to learn more about the emerging Focal Segmental Glomerulosclerosis therapies

 

Some of the key companies in the Focal Segmental Glomerulosclerosis Therapeutics Market include:

Key companies developing therapies for Focal Segmental Glomerulosclerosis are – B. Braun Melsungen AG, Beckman Coulter Inc. (Danaher), Baxter International Inc., ChemoCentryx Inc., Complexa Inc., Dimerix Ltd, Medtronic PLC, Pfizer Inc., Retrophin Inc., Variant Pharmaceuticals Inc., and others.

 

Focal Segmental Glomerulosclerosis Pipeline Analysis:

The Focal Segmental Glomerulosclerosis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Focal Segmental Glomerulosclerosis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Focal Segmental Glomerulosclerosis Treatment.
  • Focal Segmental Glomerulosclerosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Focal Segmental Glomerulosclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Focal Segmental Glomerulosclerosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Focal Segmental Glomerulosclerosis drugs and therapies

 

Focal Segmental Glomerulosclerosis Pipeline Market Drivers

  • Surge of interest in developing new therapies for FSGS, renaissance in clinical research in nephrology are some of the important factors that are fueling the Focal Segmental Glomerulosclerosis Market.

 

Focal Segmental Glomerulosclerosis Pipeline Market Barriers

  • However, the etiology and pathogenesis of Focal Segmental Glomerulosclerosis are very complex, high cost associated with the disease and other factors are creating obstacles in the Focal Segmental Glomerulosclerosis Market growth.

 

Scope of Focal Segmental Glomerulosclerosis Pipeline Drug Insight    

  • Coverage: Global
  • Key Focal Segmental Glomerulosclerosis Companies: Ceptur Therapeutics, Evergreen Therapeutics, Delta4, Certa Therapeutics, Boehringer Ingelheim, River 3 Renal Corp, Dimerix Bioscience, Travere Therapeutics, Inc., and others
  • Key Focal Segmental Glomerulosclerosis Therapies: Research programme Oligonucleotides, EG-102, D4-101-02, OCX-063, BI764198, R3R 01, DMX-200, Sparsentan, and others
  • Focal Segmental Glomerulosclerosis Therapeutic Assessment: Focal Segmental Glomerulosclerosis current marketed and Focal Segmental Glomerulosclerosis emerging therapies
  • Focal Segmental Glomerulosclerosis Market Dynamics: Focal Segmental Glomerulosclerosis market drivers and Focal Segmental Glomerulosclerosis market barriers 

 

Request for Sample PDF Report for Focal Segmental Glomerulosclerosis Pipeline Assessment and clinical trials

 

Table of Contents

1. Focal Segmental Glomerulosclerosis Report Introduction

2. Focal Segmental Glomerulosclerosis Executive Summary

3. Focal Segmental Glomerulosclerosis Overview

4. Focal Segmental Glomerulosclerosis- Analytical Perspective In-depth Commercial Assessment

5. Focal Segmental Glomerulosclerosis Pipeline Therapeutics

6. Focal Segmental Glomerulosclerosis Late Stage Products (Phase II/III)

7. Focal Segmental Glomerulosclerosis Mid Stage Products (Phase II)

8. Focal Segmental Glomerulosclerosis Early Stage Products (Phase I)

9. Focal Segmental Glomerulosclerosis Preclinical Stage Products

10. Focal Segmental Glomerulosclerosis Therapeutics Assessment

11. Focal Segmental Glomerulosclerosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Focal Segmental Glomerulosclerosis Key Companies

14. Focal Segmental Glomerulosclerosis Key Products

15. Focal Segmental Glomerulosclerosis Unmet Needs

16 . Focal Segmental Glomerulosclerosis Market Drivers and Barriers

17. Focal Segmental Glomerulosclerosis Future Perspectives and Conclusion

18. Focal Segmental Glomerulosclerosis Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. 

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Focal Segmental Glomerulosclerosis Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | B. Braun Melsungen, Beckman Coulter, Bayer

Hereditary Transthyretin Amyloidosis (hATTR) Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Ionis Pharma, AstraZeneca, Eidos, Corino, Prothena

The Hereditary Transthyretin Amyloidosis Market Forecast report offers an in-depth understanding of the Hereditary Transthyretin Amyloidosis, historical and forecasted epidemiology as well as the Hereditary Transthyretin Amyloidosis market trends in the 7MM.

DelveInsight’s “Hereditary Transthyretin Amyloidosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hereditary Transthyretin Amyloidosis, historical and forecasted epidemiology as well as the Hereditary Transthyretin Amyloidosis market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Hereditary Transthyretin Amyloidosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hereditary Transthyretin Amyloidosis Market Forecast

 

Some of the key facts of the Hereditary Transthyretin Amyloidosis Market Report: 

  • The Hereditary Transthyretin Amyloidosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In January 2024, WAINUA™ (eplontersen) is a self-administered auto-injector treatment designed for managing the polyneuropathy associated with hereditary transthyretin-mediated amyloidosis (hATTR-PN or ATTRv-PN) in adult patients. Developed by Ionis Pharmaceuticals, a biotech firm headquartered in the United States, WAINUA™ utilizes Ionis’ sophisticated LIgand-Conjugated Antisense (LICA) technology to regulate the production of transthyretin (TTR) protein. This therapeutic approach aims to address the underlying pathology of ATTR for improved patient outcomes.
  • According to DelveInsight’s examination, the total number of diagnosed prevalent cases of hereditary transthyretin amyloidosis (hATTR) in the Seven Major Markets (7MM) was approximately 15,096 in 2022. These cases are projected to rise over the study period spanning from 2019 to 2032.
  • In 2022, the United States represented close to 62% of the overall diagnosed prevalent cases of hereditary transthyretin amyloidosis (hATTR) in the Seven Major Markets (7MM). This percentage is anticipated to grow even higher by the year 2032.
  • In 2022, France had the highest number of diagnosed prevalent cases of hereditary transthyretin amyloidosis (hATTR) among the European Union Four (EU4) and the United Kingdom (UK), totaling approximately 1,593 cases. In contrast, Germany reported the lowest number of cases in this group.
  • Key Hereditary Transthyretin Amyloidosis Companies: Ionis Pharmaceuticals, AstraZeneca, Eidos Therapeutics, Corino Therapeutics, Prothena, Novo Nordisk, Intellia Therapeutics, Regeneron Pharmaceutical, and others
  • Key Hereditary Transthyretin Amyloidosis Therapies: Eplontersen, Acoramidis (AG 10), CRX-1008 (Tolcapone; SOM0226), PRX004, NTLA-2001, and others
  • The Hereditary Transthyretin Amyloidosis epidemiology based on gender analyzed that FAP is the most affected type-specific hATTR in the US
  • The Hereditary Transthyretin Amyloidosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hereditary Transthyretin Amyloidosis pipeline products will significantly revolutionize the Hereditary Transthyretin Amyloidosis market dynamics.

 

Hereditary Transthyretin Amyloidosis Overview

Hereditary Transthyretin Amyloidosis (hATTR), also known as transthyretin amyloidosis or ATTRv amyloidosis, is a rare, inherited disorder characterized by the accumulation of abnormal deposits of a protein called transthyretin (TTR) in various tissues and organs throughout the body.

 

Get a Free sample for the Hereditary Transthyretin Amyloidosis Market Report:

https://www.delveinsight.com/report-store/hereditary-amyloidosis-market

 

Hereditary Transthyretin Amyloidosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Hereditary Transthyretin Amyloidosis Epidemiology Segmentation:

The Hereditary Transthyretin Amyloidosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Hereditary Transthyretin Amyloidosis
  • Prevalent Cases of Hereditary Transthyretin Amyloidosis by severity
  • Gender-specific Prevalence of Hereditary Transthyretin Amyloidosis
  • Diagnosed Cases of Episodic and Chronic Hereditary Transthyretin Amyloidosis

 

Download the report to understand which factors are driving Hereditary Transthyretin Amyloidosis epidemiology trends @ Hereditary Transthyretin Amyloidosis Epidemiology Forecast

 

Hereditary Transthyretin Amyloidosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hereditary Transthyretin Amyloidosis market or expected to get launched during the study period. The analysis covers Hereditary Transthyretin Amyloidosis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hereditary Transthyretin Amyloidosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Hereditary Transthyretin Amyloidosis Therapies and Key Companies

  • CRX-1008 (Tolcapone; SOM0226): Corino Therapeutics
  • PRX004: Prothena/ Novo Nordisk
  • NTLA-2001: Intellia Therapeutics/Regeneron Pharmaceutical
  • Eplontersen: Ionis Pharmaceuticals/ AstraZeneca
  • Acoramidis (AG 10): Eidos Therapeutics

 

Discover more about therapies set to grab major Hereditary Transthyretin Amyloidosis market share @ Hereditary Transthyretin Amyloidosis Treatment Market

 

Hereditary Transthyretin Amyloidosis Market Strengths

  • The development and success of gene silencing therapies in hATTR amyloidosis is a breakthrough for adult-onset, neurodegenerative diseases.
  • The upcoming therapies with their novel mechanism of action hold potential to combat the unmet need faced by the patients with hATTR-CM and hATTR-PN and provide better treatment options to the patients.
  • The upcoming pipeline also includes a gene therapy based on CRISPR technology, which is currently in early phase of development. If this therapy gets approved, it could provide a cure for hATTR.

 

Hereditary Transthyretin Amyloidosis Market Opportunities

  • The unique mechanisms of action of inotersen and patisiran overcome many limitations of previous therapies for patients with hATTR.
  • Currently there is only one therapy approved for ATTR-CM in the 7MM, i.e., Vandaqel, this provides a window of opportunity for key players to develop therapies targeting ATTR-CM.
  • Additional evidence for current and emerging therapies for patients with hATTR offers much‐needed hope, along with a promise of better treatment, for this debilitating and life‐threatening disease.

 

Scope of the Hereditary Transthyretin Amyloidosis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Hereditary Transthyretin Amyloidosis Companies: Ionis Pharmaceuticals, AstraZeneca, Eidos Therapeutics, Corino Therapeutics, Prothena, Novo Nordisk, Intellia Therapeutics, Regeneron Pharmaceutical, and others
  • Key Hereditary Transthyretin Amyloidosis Therapies: Eplontersen, Acoramidis (AG 10), CRX-1008 (Tolcapone; SOM0226), PRX004, NTLA-2001, and others
  • Hereditary Transthyretin Amyloidosis Therapeutic Assessment: Hereditary Transthyretin Amyloidosis current marketed and Hereditary Transthyretin Amyloidosis emerging therapies
  • Hereditary Transthyretin Amyloidosis Market Dynamics: Hereditary Transthyretin Amyloidosis market drivers and Hereditary Transthyretin Amyloidosis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Hereditary Transthyretin Amyloidosis Unmet Needs, KOL’s views, Analyst’s views, Hereditary Transthyretin Amyloidosis Market Access and Reimbursement 

 

To know more about Hereditary Transthyretin Amyloidosis companies working in the treatment market, visit @ Hereditary Transthyretin Amyloidosis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Hereditary Transthyretin Amyloidosis Market Report Introduction

2. Executive Summary for Hereditary Transthyretin Amyloidosis

3. SWOT analysis of Hereditary Transthyretin Amyloidosis

4. Hereditary Transthyretin Amyloidosis Patient Share (%) Overview at a Glance

5. Hereditary Transthyretin Amyloidosis Market Overview at a Glance

6. Hereditary Transthyretin Amyloidosis Disease Background and Overview

7. Hereditary Transthyretin Amyloidosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Hereditary Transthyretin Amyloidosis 

9. Hereditary Transthyretin Amyloidosis Current Treatment and Medical Practices

10. Hereditary Transthyretin Amyloidosis Unmet Needs

11. Hereditary Transthyretin Amyloidosis Emerging Therapies

12. Hereditary Transthyretin Amyloidosis Market Outlook

13. Country-Wise Hereditary Transthyretin Amyloidosis Market Analysis (2019–2032)

14. Hereditary Transthyretin Amyloidosis Market Access and Reimbursement of Therapies

15. Hereditary Transthyretin Amyloidosis Market Drivers

16. Hereditary Transthyretin Amyloidosis Market Barriers

17.  Hereditary Transthyretin Amyloidosis Appendix

18. Hereditary Transthyretin Amyloidosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hereditary Transthyretin Amyloidosis (hATTR) Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Ionis Pharma, AstraZeneca, Eidos, Corino, Prothena

Amyotrophic Lateral Sclerosis Pipeline Assessment | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | GSK, Helixmith, Sanofi

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Amyotrophic Lateral Sclerosis pipeline constitutes 90+ key companies continuously working towards developing 100+ Amyotrophic Lateral Sclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Amyotrophic Lateral Sclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Amyotrophic Lateral Sclerosis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Amyotrophic Lateral Sclerosis Market.

 

Some of the key takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Amyotrophic Lateral Sclerosis treatment therapies with a considerable amount of success over the years. 
  • Amyotrophic Lateral Sclerosis companies working in the treatment market are Aeterna Zentaris, GeNeuro SA, ProJenX, QurAlis Corporation, Wave Life Sciences, Revalesio Corporation, AI THERAPEUTICS, CYTOKINETICS, Ionis Pharmaceuticals, and others, are developing therapies for the Amyotrophic Lateral Sclerosis treatment 
  • Emerging Amyotrophic Lateral Sclerosis therapies in the different phases of clinical trials are- AEZS-130, GNK 301, Prosetin, QRL 201, WVE-004, RNS60, AIT-101, Reldesemtiv, ION363, and others are expected to have a significant impact on the Amyotrophic Lateral Sclerosis market in the coming years.   
  • In December 2023, NeuroSense Therapeutics announced positive outcomes from the Phase IIb PARADIGM clinical trial of its medication candidate, PrimeC, in individuals with amyotrophic lateral sclerosis (ALS). The trial successfully achieved its primary and secondary objectives. This double-blind, randomized, multinational, and placebo-controlled study evaluated PrimeC in ALS patients across Israel, Canada, and Italy over a six-month period.
  • In November 2023, ProJenX, a biotechnology company in the clinical stage, is pioneering the development of innovative therapies that can penetrate the brain and target biologically-defined pathways for treating amyotrophic lateral sclerosis (ALS) and other severe brain disorders. Today, the company announced that Health Canada has granted authorization for its clinical trial application (CTA) for study PRO-101. This global, hybrid Phase 1 clinical trial will assess prosetin, a pioneering MAP4K inhibitor, in both healthy volunteers and individuals with ALS. The Health Canada CTA approval facilitates the commencement of Part 1c of PRO-101, which is tailored to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of prosetin in participants with ALS.
  • In September 2022, The FDA in the United States sanctioned RELYVRIO for ALS. This medication combines sodium phenylbutyrate and taurursodiol, demonstrating a decrease in the rate of decline in daily functioning during clinical assessments and correlating with extended overall survival.
  • In July 2022, Cytokinetics has started a Phase III Open-Label Extension trial called CY5032, following the completion of dosing (up to Week 48) in CY5031 (COURAGE-ALS). This study involves reldesemtiv, a selective fast skeletal muscle troponin activator, and aims to include approximately 400 ALS patients from the sites previously involved in CY5031 for the open-label extension, CY5032.
  • In April 2023, AI Therapeutics, Inc., has reported favorable outcomes from a Phase 2a clinical study involving AIT-101 (LAM002A) in individuals with C9ORF72 amyotrophic lateral sclerosis (ALS). Participants receiving AIT-101 exhibited elevated expression of the target engagement biomarker (sGPNMB) and a 73% decrease in the toxic protein aggregate (poly(GP)) over a span of 12 weeks. Additionally, the study achieved its primary goals of establishing safety and tolerability, as well as confirming the delivery of the drug and three active metabolites into the brain.

 

Amyotrophic Lateral Sclerosis Overview

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disorder that affects nerve cells in the brain and spinal cord. ALS leads to the gradual deterioration and death of motor neurons, which are the nerve cells responsible for controlling voluntary muscle movement. 

 

Get a Free Sample PDF Report to know more about Amyotrophic Lateral Sclerosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight

 

Emerging Amyotrophic Lateral Sclerosis Drugs Under Different Phases of Clinical Development Include:

  • AEZS-130: Aeterna Zentaris
  • GNK 301: GeNeuro SA
  • Prosetin: ProJenX
  • QRL 201: QurAlis Corporation
  • WVE-004: Wave Life Sciences
  • RNS60: Revalesio Corporation
  • AIT-101: AI THERAPEUTICS
  • Reldesemtiv: CYTOKINETICS
  • ION363: Ionis Pharmaceuticals

 

Amyotrophic Lateral Sclerosis Route of Administration

Amyotrophic Lateral Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Amyotrophic Lateral Sclerosis Molecule Type

Amyotrophic Lateral Sclerosis Products have been categorized under various Molecule types, such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Amyotrophic Lateral Sclerosis Pipeline Therapeutics Assessment

  • Amyotrophic Lateral Sclerosis Assessment by Product Type
  • Amyotrophic Lateral Sclerosis By Stage and Product Type
  • Amyotrophic Lateral Sclerosis Assessment by Route of Administration
  • Amyotrophic Lateral Sclerosis By Stage and Route of Administration
  • Amyotrophic Lateral Sclerosis Assessment by Molecule Type
  • Amyotrophic Lateral Sclerosis by Stage and Molecule Type

 

DelveInsight’s Amyotrophic Lateral Sclerosis Report covers around 100+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Amyotrophic Lateral Sclerosis product details are provided in the report. Download the Amyotrophic Lateral Sclerosis pipeline report to learn more about the emerging Amyotrophic Lateral Sclerosis therapies

 

Some of the key companies in the Amyotrophic Lateral Sclerosis Therapeutics Market include:

Key companies developing therapies for Amyotrophic Lateral Sclerosis are – Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, Alector, GSK, NeuroSense Therapeutics, Biogen, Ionis Pharmaceuticals, Brainstorm Cell Therapeutics, Cytokinetics, Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, AL-S Pharma, MediciNova, Seelos Theraputics, Prilenia Therapeutics, AB Science, Eledon Pharmaceuticals, Revalesio Corporation, Biohaven Pharmaceuticals, UCB Pharma, Ra Pharmaceuticals, AI Therapeutics, and others.

 

Amyotrophic Lateral Sclerosis Pipeline Analysis:

The Amyotrophic Lateral Sclerosis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Amyotrophic Lateral Sclerosis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Amyotrophic Lateral Sclerosis Treatment.
  • Amyotrophic Lateral Sclerosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Amyotrophic Lateral Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Amyotrophic Lateral Sclerosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Amyotrophic Lateral Sclerosis drugs and therapies

 

Amyotrophic Lateral Sclerosis Pipeline Market Drivers

  • Need for disease-specific treatment options, rising geriatric population, increasing research and developmental activities are some of the important factors that are fueling the Amyotrophic Lateral Sclerosis Market.

 

Amyotrophic Lateral Sclerosis Pipeline Market Barriers

  • However, No standard cure for ALS, unknown cause of the disease and other factors are creating obstacles in the Amyotrophic Lateral Sclerosis Market growth.

 

Scope of Amyotrophic Lateral Sclerosis Pipeline Drug Insight    

  • Coverage: Global
  • Key Amyotrophic Lateral Sclerosis Companies: Aeterna Zentaris, GeNeuro SA, ProJenX, QurAlis Corporation, Wave Life Sciences, Revalesio Corporation, AI THERAPEUTICS, CYTOKINETICS, Ionis Pharmaceuticals, and others
  • Key Amyotrophic Lateral Sclerosis Therapies: AEZS-130, GNK 301, Prosetin, QRL 201, WVE-004, RNS60, AIT-101, Reldesemtiv, ION363, and others
  • Amyotrophic Lateral Sclerosis Therapeutic Assessment: Amyotrophic Lateral Sclerosis current marketed and Amyotrophic Lateral Sclerosis emerging therapies
  • Amyotrophic Lateral Sclerosis Market Dynamics: Amyotrophic Lateral Sclerosis market drivers and Amyotrophic Lateral Sclerosis market barriers 

 

Request for Sample PDF Report for Amyotrophic Lateral Sclerosis Pipeline Assessment and clinical trials

 

Table of Contents

1. Amyotrophic Lateral Sclerosis Report Introduction

2. Amyotrophic Lateral Sclerosis Executive Summary

3. Amyotrophic Lateral Sclerosis Overview

4. Amyotrophic Lateral Sclerosis- Analytical Perspective In-depth Commercial Assessment

5. Amyotrophic Lateral Sclerosis Pipeline Therapeutics

6. Amyotrophic Lateral Sclerosis Late Stage Products (Phase II/III)

7. Amyotrophic Lateral Sclerosis Mid Stage Products (Phase II)

8. Amyotrophic Lateral Sclerosis Early Stage Products (Phase I)

9. Amyotrophic Lateral Sclerosis Preclinical Stage Products

10. Amyotrophic Lateral Sclerosis Therapeutics Assessment

11. Amyotrophic Lateral Sclerosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Amyotrophic Lateral Sclerosis Key Companies

14. Amyotrophic Lateral Sclerosis Key Products

15. Amyotrophic Lateral Sclerosis Unmet Needs

16 . Amyotrophic Lateral Sclerosis Market Drivers and Barriers

17. Amyotrophic Lateral Sclerosis Future Perspectives and Conclusion

18. Amyotrophic Lateral Sclerosis Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Amyotrophic Lateral Sclerosis Pipeline Assessment | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | GSK, Helixmith, Sanofi

Fibrodysplasia Ossificans Progressiva Pipeline Report, 2024 Updates : In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects and Companies

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Fibrodysplasia Ossificans Progressiva pipeline constitutes 10+ key companies continuously working towards developing 10+ Fibrodysplasia Ossificans Progressiva treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Fibrodysplasia Ossificans Progressiva Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Fibrodysplasia Ossificans Progressiva Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Fibrodysplasia Ossificans Progressiva Market.

 

Some of the key takeaways from the Fibrodysplasia Ossificans Progressiva Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Fibrodysplasia Ossificans Progressiva treatment therapies with a considerable amount of success over the years. 
  • Fibrodysplasia Ossificans Progressiva companies working in the treatment market are Daiichi Sankyo Co., Ltd, AstraZeneca, Ipsen, Incyte Corporation, Nobelpharma, Regeneron Pharmaceuticals, and others, are developing therapies for the Fibrodysplasia Ossificans Progressiva treatment 
  • Emerging Fibrodysplasia Ossificans Progressiva therapies in the different phases of clinical trials are- DS 6016, Saracatinib, Fidrisertib, INCB-00928, NPC-12T, Garetosmab, and others are expected to have a significant impact on the Fibrodysplasia Ossificans Progressiva market in the coming years.   
  • In June 2023,  Ipsen (Euronext: IPN; ADR: IPSEY) announced that the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) approved investigational palovarotene as an effective treatment for people with the extremely rare bone disease fibrodysplasia ossificans progressiva (FOP), with a favourable risk-benefit profile. Palovarotene’s New Drug Application (NDA) is being reviewed by the FDA, and a decision is expected on August 16, 2023. Palovarotene will be the first FOP medication offered in the US if approved
  • In November 2022, A trial titled “Phase 3 Randomised, PlaceboControlled Study to Assess Safety, Tolerability, and Efficacy of Garetosmab in Patients With Fibrodysplasia Ossificans Progressiva” was started by Regeneron Pharmaceuticals.

 

Fibrodysplasia Ossificans Progressiva Overview

Heterotopic ossification, a very rare genetic connective tissue illness, causes abnormal bone growth in parts of the body other than those where bone is ordinarily found, such as the ligaments, tendons, and skeletal muscles.

 

Get a Free Sample PDF Report to know more about Fibrodysplasia Ossificans Progressiva Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/fibrodysplasia-ossificans-progressiva-fop-pipeline-insight

 

Emerging Fibrodysplasia Ossificans Progressiva Drugs Under Different Phases of Clinical Development Include:

  • DS 6016: Daiichi Sankyo Co., Ltd
  • Saracatinib: AstraZeneca
  • Fidrisertib: Ipsen
  • INCB-00928: Incyte Corporation
  • NPC-12T: Nobelpharma
  • Garetosmab: Regeneron Pharmaceuticals

 

Fibrodysplasia Ossificans Progressiva Route of Administration

Fibrodysplasia Ossificans Progressiva pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Intravenous
  • Subcutaneous
  • Intramuscular

 

Fibrodysplasia Ossificans Progressiva Molecule Type

Fibrodysplasia Ossificans Progressiva Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide

 

Fibrodysplasia Ossificans Progressiva Pipeline Therapeutics Assessment

  • Fibrodysplasia Ossificans Progressiva Assessment by Product Type
  • Fibrodysplasia Ossificans Progressiva By Stage and Product Type
  • Fibrodysplasia Ossificans Progressiva Assessment by Route of Administration
  • Fibrodysplasia Ossificans Progressiva By Stage and Route of Administration
  • Fibrodysplasia Ossificans Progressiva Assessment by Molecule Type
  • Fibrodysplasia Ossificans Progressiva by Stage and Molecule Type

 

DelveInsight’s Fibrodysplasia Ossificans Progressiva Report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Fibrodysplasia Ossificans Progressiva product details are provided in the report. Download the Fibrodysplasia Ossificans Progressiva pipeline report to learn more about the emerging Fibrodysplasia Ossificans Progressiva therapies

 

Some of the key companies in the Fibrodysplasia Ossificans Progressiva Therapeutics Market include:

Key companies developing therapies for Fibrodysplasia Ossificans Progressiva are – Ipsen, Blueprint Medicines, Regeneron Pharmaceuticals, Daiichi Sankyo, Inc., AstraZeneca, Incyte Corporation, and others.

 

Fibrodysplasia Ossificans Progressiva Pipeline Analysis:

The Fibrodysplasia Ossificans Progressiva pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Fibrodysplasia Ossificans Progressiva with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Fibrodysplasia Ossificans Progressiva Treatment.
  • Fibrodysplasia Ossificans Progressiva key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Fibrodysplasia Ossificans Progressiva Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Fibrodysplasia Ossificans Progressiva market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Fibrodysplasia Ossificans Progressiva drugs and therapies

 

Fibrodysplasia Ossificans Progressiva Pipeline Market Drivers

  • Rising incidence of Fibrodysplasia Ossificans Progressiva (FOP), increase in awareness associated with FOP are some of the important factors that are fueling the Fibrodysplasia Ossificans Progressiva Market.

 

Fibrodysplasia Ossificans Progressiva Pipeline Market Barriers

  • However, poor understanding of the disease, the rate of misdiagnosis of the disease is higher and other factors are creating obstacles in the Fibrodysplasia Ossificans Progressiva Market growth.

 

Scope of Fibrodysplasia Ossificans Progressiva Pipeline Drug Insight    

  • Coverage: Global
  • Key Fibrodysplasia Ossificans Progressiva Companies: Daiichi Sankyo Co., Ltd, AstraZeneca, Ipsen, Incyte Corporation, Nobelpharma, Regeneron Pharmaceuticals, and others
  • Key Fibrodysplasia Ossificans Progressiva Therapies: DS 6016, Saracatinib, Fidrisertib, INCB-00928, NPC-12T, Garetosmab, and others
  • Fibrodysplasia Ossificans Progressiva Therapeutic Assessment: Fibrodysplasia Ossificans Progressiva current marketed and Fibrodysplasia Ossificans Progressiva emerging therapies
  • Fibrodysplasia Ossificans Progressiva Market Dynamics: Fibrodysplasia Ossificans Progressiva market drivers and Fibrodysplasia Ossificans Progressiva market barriers 

 

Request for Sample PDF Report for Fibrodysplasia Ossificans Progressiva Pipeline Assessment and clinical trials

 

Table of Contents

1. Fibrodysplasia Ossificans Progressiva Report Introduction

2. Fibrodysplasia Ossificans Progressiva Executive Summary

3. Fibrodysplasia Ossificans Progressiva Overview

4. Fibrodysplasia Ossificans Progressiva- Analytical Perspective In-depth Commercial Assessment

5. Fibrodysplasia Ossificans Progressiva Pipeline Therapeutics

6. Fibrodysplasia Ossificans Progressiva Late Stage Products (Phase II/III)

7. Fibrodysplasia Ossificans Progressiva Mid Stage Products (Phase II)

8. Fibrodysplasia Ossificans Progressiva Early Stage Products (Phase I)

9. Fibrodysplasia Ossificans Progressiva Preclinical Stage Products

10. Fibrodysplasia Ossificans Progressiva Therapeutics Assessment

11. Fibrodysplasia Ossificans Progressiva Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Fibrodysplasia Ossificans Progressiva Key Companies

14. Fibrodysplasia Ossificans Progressiva Key Products

15. Fibrodysplasia Ossificans Progressiva Unmet Needs

16 . Fibrodysplasia Ossificans Progressiva Market Drivers and Barriers

17. Fibrodysplasia Ossificans Progressiva Future Perspectives and Conclusion

18. Fibrodysplasia Ossificans Progressiva Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Fibrodysplasia Ossificans Progressiva Pipeline Report, 2024 Updates : In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects and Companies

Onychomycosis Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Merck, Novartis, Novartis, Pfizer, Bayer, Topica Pharma

The Onychomycosis Market Forecast report offers an in-depth understanding of the Onychomycosis, historical and forecasted epidemiology as well as the Onychomycosis market trends in the 7MM.

DelveInsight’s “Onychomycosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Onychomycosis, historical and forecasted epidemiology as well as the Onychomycosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Onychomycosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Onychomycosis Market Forecast

 

Some of the key facts of the Onychomycosis Market Report: 

  • The Onychomycosis market size was valued approximately USD 1,757 million in 2022 in the United States and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In 2022, Germany boasted the largest market size among European countries, totaling nearly USD 275 million, while France followed closely with over USD 218 million in the same year.
  • In June 2023, Emblation, a medical technology company based in Scotland, has initiated a clinical trial in Canada to explore the effectiveness of its Swift microwave skin therapy device in treating onychomycosis, commonly referred to as toenail fungus.
  • The total prevalence cases in the 7MM were determined. The estimated number of onychomycosis cases worldwide (7MMprevalent cases) in 2022 was close to 85,435,000, with the majority of cases being found in the US
  • More than 13,390,000 cases of onychomycosis were diagnosed in total in the EU4 and UK markets in 2022, and this number is anticipated to climb during the projection period (2023–2022)
  • The overall number of prevalent cases in Japan in 2022 exceeded 12,763,000
  • According to analysts, there were roughly 4,000,000 mild cases, about 6,000,000 moderate cases, and about 5,000,000 severe cases of onychomycosis in the United States
  • Key Onychomycosis Companies: Moberg Pharma, Blueberry Therapeutics, Hallux, Pfizer, MediQuest Therapeutics, Polichem S.A, Repolar Ltd., Celtic Pharma, GlaxoSmithKline, Hisamitsu Pharma, Polichem S.A., Pfizer, Bausch Health, Halcygen Pharma, Meiji Seika Pharma, photonamic GmbH, Viamet, Novartis, Topica Pharma, Taro Pharma, NanoBio Crp, Hallux, Inc., Merck Sharp & Dohme, Bayer, Abeona Therapeutics, Dow Pharma, Taro Pharma, and others
  • Key Onychomycosis Therapies: MOB-015, BB2603, HSG, Tavaborole, MOB015B, P-3058, Organogel of naftifine, Amorolfine, TDT067 and Lamisil, Albaconazole, HTU-520, P-3058, AN2690, Efinaconazole, SUBA-itraconazole, ME1111, PD P 506 A, VT-1161, terbinafine, Luliconazole, NVXT topical, NB-002, HTS-519, SCH 56592, Bifonazole cream 1%, EcoNail™, IDP-108, Itraconazole, and others
  • The Onychomycosis epidemiology based on gender analyzed that Onychomycosis is more common in females than males, in the United States
  • The Onychomycosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Onychomycosis pipeline products will significantly revolutionize the Onychomycosis market dynamics.

 

Onychomycosis Overview

Onychomycosis, often referred to as toenail fungus or nail fungal infection, is a common fungal infection that affects the toenails or fingernails. It typically occurs when fungi, such as dermatophytes, invade the nail bed, nail plate, or surrounding skin, leading to discoloration, thickening, and brittleness of the nails.

 

Get a Free sample for the Onychomycosis Market Report:

https://www.delveinsight.com/report-store/onychomycosis-market

 

Onychomycosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Onychomycosis Epidemiology Segmentation:

The Onychomycosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Onychomycosis
  • Prevalent Cases of Onychomycosis by severity
  • Gender-specific Prevalence of Onychomycosis
  • Diagnosed Cases of Episodic and Chronic Onychomycosis

 

Download the report to understand which factors are driving Onychomycosis epidemiology trends @ Onychomycosis Epidemiology Forecast

 

Onychomycosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Onychomycosis market or expected to get launched during the study period. The analysis covers Onychomycosis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Onychomycosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Onychomycosis Therapies and Key Companies

  • MOB-015: Moberg Pharma
  • BB2603: Blueberry Therapeutics
  • HSG: Hallux
  • Tavaborole: Pfizer
  • MOB015B: Moberg Pharma AB
  • P-3058: Polichem S.A.
  • Organogel of naftifine: MediQuest Therapeutics
  • Amorolfine: Repolar Ltd.
  • TDT067 and Lamisil: Celtic Pharma
  • Albaconazole: GlaxoSmithKline
  • HTU-520: Hisamitsu Pharma
  • P-3058: Polichem S.A.
  • AN2690: Pfizer
  • Efinaconazole: Bausch Health
  • SUBA-itraconazole: Halcygen Pharma
  • ME1111: Meiji Seika Pharma
  • PD P 506 A: photonamic GmbH
  • VT-1161: Viamet
  • terbinafine: Novartis
  • Luliconazole: Topica Pharma
  • NVXT topical: Taro Pharma
  • NB-002: NanoBio Crp
  • HTS-519: Hallux, Inc.
  • SCH 56592: Merck Sharp & Dohme
  • Bifonazole cream 1%: Bayer
  • EcoNail™: Abeona Therapeutics
  • IDP-108: Dow Pharma
  • Itraconazole: Taro Pharma

 

Discover more about therapies set to grab major Onychomycosis market share @ Onychomycosis Treatment Market

 

Onychomycosis Market Strengths

  • The introduction of novel, inexpensive, and non-invasive diagnostic technologies have led to rapid and accurate diagnosis of onychomycosis, hence increased the rate of diagnosis.

 

Onychomycosis Market Opportunities

  • Current treatments have poor adherence and tolerability creating an opportunity for the key players to work on these areas

 

Scope of the Onychomycosis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Onychomycosis Companies: Moberg Pharm, Blueberry Therapeutics, Hallux, Pfizer, MediQuest Therapeutics, Moberg Pharma AB, Polichem S.A, Repolar Ltd., Celtic Pharma, GlaxoSmithKline, Hisamitsu Pharma, Polichem S.A., Pfizer, Bausch Health, Halcygen Pharma, Meiji Seika Pharma, photonamic GmbH, Viamet, Novartis, Topica Pharma, Taro Pharma, NanoBio Crp, Hallux, Inc., Merck Sharp & Dohme, Bayer, Abeona Therapeutics, Dow Pharma, Taro Pharma, and others
  • Key Onychomycosis Therapies: MOB-015, BB2603, HSG, Tavaborole, MOB015B, P-3058, Organogel of naftifine, Amorolfine, TDT067 and Lamisil, Albaconazole, HTU-520, P-3058, AN2690, Efinaconazole, SUBA-itraconazole, ME1111, PD P 506 A, VT-1161, terbinafine, Luliconazole, NVXT topical, NB-002, HTS-519, SCH 56592, Bifonazole cream 1%, EcoNail™, IDP-108, Itraconazole, and others
  • Onychomycosis Therapeutic Assessment: Onychomycosis current marketed and Onychomycosis emerging therapies
  • Onychomycosis Market Dynamics: Onychomycosis market drivers and Onychomycosis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Onychomycosis Unmet Needs, KOL’s views, Analyst’s views, Onychomycosis Market Access and Reimbursement 

 

To know more about Onychomycosis companies working in the treatment market, visit @ Onychomycosis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Onychomycosis Market Report Introduction

2. Executive Summary for Onychomycosis

3. SWOT analysis of Onychomycosis

4. Onychomycosis Patient Share (%) Overview at a Glance

5. Onychomycosis Market Overview at a Glance

6. Onychomycosis Disease Background and Overview

7. Onychomycosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Onychomycosis 

9. Onychomycosis Current Treatment and Medical Practices

10. Onychomycosis Unmet Needs

11. Onychomycosis Emerging Therapies

12. Onychomycosis Market Outlook

13. Country-Wise Onychomycosis Market Analysis (2019–2032)

14. Onychomycosis Market Access and Reimbursement of Therapies

15. Onychomycosis Market Drivers

16. Onychomycosis Market Barriers

17.  Onychomycosis Appendix

18. Onychomycosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Onychomycosis Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Merck, Novartis, Novartis, Pfizer, Bayer, Topica Pharma

Community-Acquired Bacterial Pneumonia Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Johnson & Johnson, Pfizer Inc., Dainippon

The Community-Acquired Bacterial Pneumonia Market Forecast report offers an in-depth understanding of the Community-Acquired Bacterial Pneumonia, historical and forecasted epidemiology as well as the Community-Acquired Bacterial Pneumonia market trends in the 7MM.

DelveInsight’s “Community-Acquired Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Community-Acquired Bacterial Pneumonia, historical and forecasted epidemiology as well as the Community-Acquired Bacterial Pneumonia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Community-Acquired Bacterial Pneumonia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Community-Acquired Bacterial Pneumonia Market Forecast

 

Some of the key facts of the Community-Acquired Bacterial Pneumonia Market Report: 

  • The Community-Acquired Bacterial Pneumonia market size was valued USD 2,616 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In April 2024, The US Food and Drug Administration (FDA) has granted approval to Basilea Pharmaceutica’s Zevtera (ceftobiprole medocaril sodium for injection), an antibiotic designed to address various infections. Zevtera is authorized for use in adults with staphylococcus aureus bloodstream infections (SAB) and acute bacterial skin and skin structure infections (ABSSSI). Additionally, it is indicated for the treatment of community-acquired bacterial pneumonia (CABP) in both adult and pediatric patients aged three months and older.
  • CAP continues to be a major source of morbidity and mortality in the US, affecting 649 to 847 persons per 100,000 people and leading to over 1.6 million hospital admissions annually. More than 5 million new cases of CAP are diagnosed each year in the United States; 80% of these cases receive outpatient care with a death rate of less than 1%, and 20% receive inpatient care with a mortality rate of 12% to 40% (Sattar & Sharma, 2021)
  • Males had a greater incidence of CAP than females did (15.56; 95% CI, 13.90e17.43) versus 9.11 (7.87e10.55) per 10,000 people; p 0.0001. Males had greater incidence rates than females did (p 0.0001), and they rose with age
  • DelveInsight calculated that there were 6,886,685 incident cases of community-acquired bacterial pneumonia (CABP) in the 7MM people
  • Germany had the most Community-Acquired Bacterial Pneumonia (CABP) incident instances among the EU5 nations, with 568,953 cases in 2019
  • Key Community-Acquired Bacterial Pneumonia Companies: Paratek Pharmaceuticals, Forest Laboratories, Melinta Therapeutics, Inc., Chia Tai Tianqing Pharma, Nabriva Therapeutics, Biotest, ACM, AstraZeneca, Eagle Pharma, Cubist Pharma, Johnson & Johnson, Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharmaceutical Company Limited, Basilea Pharmaceutica, and others
  • Key Community-Acquired Bacterial Pneumonia Therapies: Omadacycline, Ceftaroline, Delafloxacin, Faropenem, lefamulin, Omadacycline, BT086, Nafithromycin, Ceftaroline fosamil, tigecycline, CAL02, daptomycin, Levofloxacin, and others
  • The Community-Acquired Bacterial Pneumonia epidemiology based on gender analyzed that Male ratio is more compare to Female ratio in the case of Community-Acquired Bacterial Pneumonia (CABP)
  • The Community-Acquired Bacterial Pneumonia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Community-Acquired Bacterial Pneumonia pipeline products will significantly revolutionize the Community-Acquired Bacterial Pneumonia market dynamics.

 

Community-Acquired Bacterial Pneumonia Overview

Community-Acquired Bacterial Pneumonia (CABP) is a type of pneumonia that occurs when bacteria infect the lungs and cause inflammation in individuals who have not recently been hospitalized or resided in long-term care facilities. It is one of the most common types of pneumonia and can be caused by various bacteria, including Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Legionella pneumophila, and others.

 

Get a Free sample for the Community-Acquired Bacterial Pneumonia Market Report 

https://www.delveinsight.com/report-store/community-acquired-bacterial-pneumonia-cabp-market

 

Community-Acquired Bacterial Pneumonia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Community-Acquired Bacterial Pneumonia Epidemiology Segmentation:

The Community-Acquired Bacterial Pneumonia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Community-Acquired Bacterial Pneumonia
  • Prevalent Cases of Community-Acquired Bacterial Pneumonia by severity
  • Gender-specific Prevalence of Community-Acquired Bacterial Pneumonia
  • Diagnosed Cases of Episodic and Chronic Community-Acquired Bacterial Pneumonia

 

Download the report to understand which factors are driving Community-Acquired Bacterial Pneumonia epidemiology trends @ Community-Acquired Bacterial Pneumonia Epidemiology Forecast

 

Community-Acquired Bacterial Pneumonia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Community-Acquired Bacterial Pneumonia market or expected to get launched during the study period. The analysis covers Community-Acquired Bacterial Pneumonia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Community-Acquired Bacterial Pneumonia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Community-Acquired Bacterial Pneumonia Therapies and Key Companies

  • Omadacycline: Paratek Pharmaceuticals
  • Ceftaroline: Forest Laboratories
  • Delafloxacin: Melinta Therapeutics, Inc.
  • Faropenem: Chia Tai Tianqing Pharma
  • lefamulin: Nabriva Therapeutics
  • Omadacycline: Paratek Pharma
  • BT086: Biotest
  • Nafithromycin: ACM
  • Ceftaroline fosamil: AstraZeneca
  • tigecycline: Pfizer
  • CAL02: Eagle Pharma
  • daptomycin: Cubist Pharma
  • Levofloxacin: Johnson & Johnson

 

Discover more about therapies set to grab major Community-Acquired Bacterial Pneumonia market share @ Community-Acquired Bacterial Pneumonia Treatment Market

 

Scope of the Community-Acquired Bacterial Pneumonia Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Community-Acquired Bacterial Pneumonia Companies: Paratek Pharmaceuticals, Forest Laboratories, Melinta Therapeutics, Inc., Chia Tai Tianqing Pharma, Nabriva Therapeutics, Biotest, ACM, AstraZeneca, Eagle Pharma, Cubist Pharma, Johnson & Johnson, Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharmaceutical Company Limited, Basilea Pharmaceutica, and others
  • Key Community-Acquired Bacterial Pneumonia Therapies: Omadacycline, Ceftaroline, Delafloxacin, Faropenem, lefamulin, Omadacycline, BT086, Nafithromycin, Ceftaroline fosamil, tigecycline, CAL02, daptomycin, Levofloxacin, and others
  • Community-Acquired Bacterial Pneumonia Therapeutic Assessment: Community-Acquired Bacterial Pneumonia current marketed and Community-Acquired Bacterial Pneumonia emerging therapies
  • Community-Acquired Bacterial Pneumonia Market Dynamics: Community-Acquired Bacterial Pneumonia market drivers and Community-Acquired Bacterial Pneumonia market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Community-Acquired Bacterial Pneumonia Unmet Needs, KOL’s views, Analyst’s views, Community-Acquired Bacterial Pneumonia Market Access and Reimbursement 

 

To know more about Community-Acquired Bacterial Pneumonia companies working in the treatment market, visit @ Community-Acquired Bacterial Pneumonia Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Community-Acquired Bacterial Pneumonia Market Report Introduction

2. Executive Summary for Community-Acquired Bacterial Pneumonia

3. SWOT analysis of Community-Acquired Bacterial Pneumonia

4. Community-Acquired Bacterial Pneumonia Patient Share (%) Overview at a Glance

5. Community-Acquired Bacterial Pneumonia Market Overview at a Glance

6. Community-Acquired Bacterial Pneumonia Disease Background and Overview

7. Community-Acquired Bacterial Pneumonia Epidemiology and Patient Population

8. Country-Specific Patient Population of Community-Acquired Bacterial Pneumonia 

9. Community-Acquired Bacterial Pneumonia Current Treatment and Medical Practices

10. Community-Acquired Bacterial Pneumonia Unmet Needs

11. Community-Acquired Bacterial Pneumonia Emerging Therapies

12. Community-Acquired Bacterial Pneumonia Market Outlook

13. Country-Wise Community-Acquired Bacterial Pneumonia Market Analysis (2019–2032)

14. Community-Acquired Bacterial Pneumonia Market Access and Reimbursement of Therapies

15. Community-Acquired Bacterial Pneumonia Market Drivers

16. Community-Acquired Bacterial Pneumonia Market Barriers

17.  Community-Acquired Bacterial Pneumonia Appendix

18. Community-Acquired Bacterial Pneumonia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Community-Acquired Bacterial Pneumonia Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Johnson & Johnson, Pfizer Inc., Dainippon